4.8 Article

Immunology and the elusive AIDS vaccine

Journal

NATURE
Volume 464, Issue 7286, Pages 224-231

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature08898

Keywords

-

Funding

  1. National Institutes of Health
  2. Bill and Melinda Gates Foundation
  3. Mark and Lisa Schwartz Foundation

Ask authors/readers for more resources

Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many question whether this goal is achievable. Natural immunity is not protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yielded disappointing results. Nevertheless, there is an indication that success may be possible, but this will be dependent on understanding the antiviral immune response in unprecedented depth to identify and engineer the types of immunity required. Here we outline fundamental immunological questions that need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much broader scientific community to achieve this goal.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available